b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">31754941</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>01</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Print">2198-6576</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>7</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Mar</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Rheumatology and therapy</Title>\n                <ISOAbbreviation>Rheumatol Ther</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>121-131</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40744-019-00183-6</ELocationID>\n            <Abstract>\n                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients with rheumatoid arthritis (RA) are at an increased risk of developing malignancies, but it is unclear whether this increased risk is the result of disease pathobiology or immunosuppressant treatments for RA. This analysis evaluated the potential risk of malignancy in patients with RA treated with rituximab (MabThera<sup>\xc2\xae</sup>/Rituxan<sup>\xc2\xae</sup>) a CD20+\xe2\x80\x89B-cell depleting agent manufactured by F. Hoffmann-La Roche Ltd.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">Malignancy rates were obtained from the rituximab global company safety database for adverse event reporting and from the rituximab global clinical trial program for RA consisting of eight randomized clinical trials, two long-term open-label extensions, and one open-label prospective study. Global company safety database searches were performed using the standard Medical Dictionary for Regulatory Activities (MedDRA) queries &quot;Malignant tumors wide&quot; and &quot;Skin malignant tumors wide&quot; up to April 30, 2017. Age- and sex-specific comparator values from the general population were obtained from the US National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">For the 409,706 patients with RA in the rituximab global company safety database since first market approval in 2006, 1739 cumulative malignant events were reported, with an overall malignancy reporting rate of approximately 4.2 events per 1000 patients. No evidence of increased risk of malignancy, of any organ-specific type, was found following rituximab treatment. The rate of malignancies from rituximab-treated patients in RA clinical trials was 7.4 per 1000 patient-years. This is within the expected range, with no evidence for increased risk over time or with additional rituximab courses.</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Analyses of the global postmarketing safety database and long-term clinical trial data showed no evidence of an increased risk of malignancy of any type following rituximab treatment in patients with RA.</AbstractText>\n                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">F. Hoffmann-La Roche Ltd.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Emery</LastName>\n                    <ForeName>Paul</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Furst</LastName>\n                    <ForeName>Daniel E</ForeName>\n                    <Initials>DE</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>University of Washington, Seattle, WA, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>University of Florence, Florence, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kirchner</LastName>\n                    <ForeName>Petra</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Melega</LastName>\n                    <ForeName>Simone</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lacey</LastName>\n                    <ForeName>Stuart</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Roche Products Ltd, Welwyn Garden City, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lehane</LastName>\n                    <ForeName>Patricia B</ForeName>\n                    <Initials>PB</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Roche Products Ltd, Welwyn Garden City, UK. patricia.lehane@roche.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>21</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Rheumatol Ther</MedlineTA>\n            <NlmUniqueID>101674543</NlmUniqueID>\n            <ISSNLinking>2198-6576</ISSNLinking>\n        </MedlineJournalInfo>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Database</Keyword>\n            <Keyword MajorTopicYN="N">Malignancy</Keyword>\n            <Keyword MajorTopicYN="N">Real-world</Keyword>\n            <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>\n            <Keyword MajorTopicYN="N">Rituximab</Keyword>\n            <Keyword MajorTopicYN="N">Safety</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>03</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31754941</ArticleId>\n            <ArticleId IdType="doi">10.1007/s40744-019-00183-6</ArticleId>\n            <ArticleId IdType="pii">10.1007/s40744-019-00183-6</ArticleId>\n            <ArticleId IdType="pmc">PMC7021875</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>J Rheumatol. 2005 Nov;32(11):2130-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16265690</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Care Res (Hoboken). 2012 May;64(5):625-39</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22473917</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2011 Jan;70(1):39-46</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20937671</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Res Ther. 2015 Aug 15;17:212</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26271620</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cytokine. 2018 Jan;101:78-88</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27688201</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2013 Sep 1;72(9):1496-502</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23136242</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Rheumatology (Oxford). 2011 Aug;50(8):1431-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21415022</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2010 Sep;69(9):1629-35</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20488885</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2005 Oct;64(10):1421-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15829572</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2004 Jun 17;350(25):2572-81</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15201414</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2017 Jun;76(6):1064-1069</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27899372</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Rheumatology (Oxford). 2010 Sep;49(9):1683-93</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20463186</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Care Res (Hoboken). 2018 Oct 8;:</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30295434</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2017 Jun;76(6):1101-1136</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28298374</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA Intern Med. 2017 Nov 1;177(11):1605-1612</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28975211</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA. 2012 Sep 5;308(9):898-908</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22948700</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Semin Arthritis Rheum. 2019 Oct;49(2):222-228</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30967248</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2011 Nov;70(11):1895-904</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21885875</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2017 Jun;76(6):960-977</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28264816</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Rheum. 2007 Dec;56(12):3896-908</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18050221</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Rheumatology (Oxford). 2016 Nov;55(11):2033-2039</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27550304</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Rheumatology (Oxford). 2015 Jul;54(7):1153-60</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25477054</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Rheum. 2006 Sep;54(9):2793-806</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16947627</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 1996 Sep;32A(10):1753-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">8983286</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2016 May;75(5):831-41</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25902789</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Rheum. 2006 May;54(5):1390-400</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16649186</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Res Ther. 2008;10(2):R45</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18433475</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Rheum. 2010 Jan;62(1):64-74</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20039397</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Rheumatol. 2015 Mar;42(3):372-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25593230</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Rheumatol. 2010 May;37(5):917-27</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20194448</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Rheumatol. 2015 Oct;42(10):1761-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26276965</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Arthritis Rheum. 2007 Sep;56(9):2886-95</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17729297</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>RMD Open. 2016 May 10;2(1):e000213</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27252893</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2010 Jul 15;363(3):221-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20647199</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'